Compugen Ltd. (CGEN)
Market Cap | 143.07M |
Revenue (ttm) | 27.86M |
Net Income (ttm) | -14.23M |
Shares Out | 93.51M |
EPS (ttm) | -0.16 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 136,324 |
Open | 1.520 |
Previous Close | 1.520 |
Day's Range | 1.520 - 1.535 |
52-Week Range | 1.350 - 2.660 |
Beta | 2.98 |
Analysts | Strong Buy |
Price Target | 4.00 (+161.44%) |
Earnings Date | Mar 4, 2025 |
About CGEN
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company’s pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/T... [Read more]
Financial Performance
In 2024, Compugen's revenue was $27.86 million, a decrease of -16.72% compared to the previous year's $33.46 million. Losses were -$14.23 million, -24.12% less than in 2023.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for CGEN stock is "Strong Buy" and the 12-month stock price forecast is $4.0.
News

Compugen to Participate in Multiple Virtual Investor Conferences in April 2025
HOLON, Israel , March 26, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...

Compugen Ltd. (CGEN) Q4 2024 Earnings Call Transcript
Compugen Ltd. (NASDAQ:CGEN) Q4 2024 - Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Yvonne Naughton - VP, Head of IR and Corporate Communications Anat Cohen-Dayag - President...

Compugen Reports Fourth Quarter and Full Year 2024 Results
Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibody On track to initiate a randomized adaptive platform trial of COM701 maintenanc...

Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference
HOLON, ISRAEL , March 3, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...

Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology
Gene structure information identified by combining Compugen's AI/ML predictive computational discovery platform, Unigen™ with Ultima's UG 100™ sequencing platform to better understand tumor biology an...

Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025
HOLON, Israel , Feb. 18, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, ...

Compugen: Immuno-Oncology Innovator Poised For A Comeback
Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein, offering potential upside, despite current market skepticism. With $113.2 million in cash an...

Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
HOLON, Israel , Feb. 4, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced th...

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors
New approach to harness cytokine biology to treat cancer patients advances to the clinic First patient dosed with potential first-in-class anti-IL-18 binding protein antibody, COM503, licensed to Gile...

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
Broad method of use patent protection for COM902, a potential best-in-class reduced Fc, clinical stage, anti-TIGIT antibody, in triple combination with any anti-PD-1 antibody and any anti-PVRIG antibo...

Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript
Start Time: 08:30 January 1, 0000 9:30 AM ET Compugen Ltd. (NASDAQ:CGEN) Q3 2024 Earnings Call November 12, 2024, 08:30 AM ET Company Participants Anat Cohen-Dayag - President and CEO David Silberman...

Compugen Reports Third Quarter 2024 Results
Clinical data presented at SITC 2024 demonstrated COM701 (anti-PVRIG) mediated anti-tumor activity with durable responses and good tolerability profile in tumors typically not responding to immunother...

Compugen to Participate in Stifel 2024 Healthcare Conference
HOLON, Israel , Nov. 11, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced t...

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024
HOLON, ISRAEL , Nov. 5, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced th...

Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
HOLON, Israel , Oct. 29, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, ...

Compugen to Present New Clinical Data at SITC 2024
HOLON, Israel , Oct. 7, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, t...

Compugen to Present at Single Cell Genomics 2024 Conference
HOLON, Israel , Sept. 9, 2024 /PRNewswire/ -- Compugen Ltd.

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
HOLON, Israel , Aug. 29, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...

Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript
Compugen Ltd. (NASDAQ:CGEN) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Anat Cohen-Dayag ...

Compugen Reports Second Quarter 2024 Results
FDA clearance of COM503 IND in July 2024 triggered a $30 million milestone payment from Gilead On track to present data from COM701 + COM902 + pembrolizumab, platinum resistant ovarian cancer study i...

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harness cytokine biology for cancer th...

Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024
HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced t...

Compugen to Present at Upcoming Antibody Industrial Symposium
HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in first-line nonsquamous non-small cell lung cancer Broadening th...

Compugen Ltd. (CGEN) Q1 2024 Earnings Call Transcript
Compugen Ltd. (NASDAQ:CGEN) Q1 2024 Earnings Call Transcript May 20, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of IR & Corporate Communications Anat Cohen-Dayag - President and CEO ...